In a decisive move reflecting its strengthened strategic direction, THG PLC has firmly rejected an unsolicited proposal from Selkirk Capital Partners to acquire its flagship Myprotein brand. The Board of THG described Selkirk’s approach as highly conditional, largely unfunded, and fundamentally undervaluing Myprotein’s current performance and future prospects. The company confirmed that no further engagement with Selkirk has taken place since the offer was declined.
The rejected bid, which speculated headline valuations between £400 million and £600 million on a cash-free, debt-free basis, signals growing external interest in Myprotein’s market leadership in the global sports nutrition segment. However, THG’s rejection underscores its clear commitment to an independent growth trajectory, especially following its recent Ingenuity demerger and successful refinancing activities that have substantially fortified its balance sheet.
Why Did THG Reject Selkirk’s Proposal for Myprotein?
THG’s Board, after thorough deliberation, considered Selkirk’s proposal unfit for acceptance on multiple grounds. Firstly, the offer structure was heavily skewed toward newly issued Selkirk shares, which carried inherent market and liquidity risks. Secondly, the cash component intended to fund the remainder of the acquisition was contingent upon a new equity and debt issuance, a plan THG said lacked sufficient credibility and detail regarding its execution.
Additionally, THG emphasized that the proposal introduced substantial execution complexity. With Selkirk’s ability to secure adequate funding appearing uncertain, the Board deemed the overall proposal precarious. The valuation range of £400 million to £600 million was considered inadequate when measured against Myprotein’s performance benchmarks, its brand equity, and its long-term expansion potential in key markets such as the United States, Europe, and Asia-Pacific.
By rejecting the offer, THG has clearly signaled that it believes Myprotein’s value far exceeds the price put forth by Selkirk, especially as the brand continues to gain market share in a rapidly expanding health, wellness, and fitness sector.
What Strategic Moves Has THG Made After the Ingenuity Demerger?
The firm stance taken by THG on the Myprotein proposal comes in the backdrop of significant corporate restructuring. On 2 January 2025, THG officially completed the demerger of its Ingenuity business, a decision designed to streamline its operational focus and unlock greater shareholder value. The Ingenuity platform, which provides end-to-end e-commerce solutions, had previously been a key component of THG’s diversified offering, but its separation has allowed THG to concentrate more intensely on its beauty, nutrition, and lifestyle divisions.
Parallel to the demerger, THG undertook a successful refinancing initiative. The group reduced both gross and net debt, secured long-term banking facilities, and significantly improved its liquidity profile. These actions have not only enhanced financial flexibility but have also positioned THG to pursue its growth and cash generation strategy with renewed vigor.
Against this strengthened financial backdrop, the Board’s rejection of an opportunistic, conditional, and underfunded approach from Selkirk appears even more justified. THG’s leadership reiterated its focus on executing internal strategies to drive organic expansion rather than entertaining external offers perceived as undermining intrinsic shareholder value.
How Is THG Positioned for Future Growth Following the Selkirk Rejection?
Industry analysts observe that THG’s emphasis on organic growth, balance sheet strength, and operational focus could lead to significant upside potential, particularly in the nutrition category, where Myprotein remains a dominant force. The global sports nutrition market continues to witness double-digit growth rates, driven by rising health awareness, increased demand for protein supplements, and evolving consumer lifestyles prioritizing fitness.
Myprotein, THG’s largest and most recognizable nutrition brand, has successfully diversified its portfolio across products such as plant-based protein, functional foods, and activewear, while investing heavily in personalization and direct-to-consumer digital platforms. These strategic initiatives are expected to enhance customer lifetime value and margin expansion in coming quarters.
The Board’s decision to dismiss Selkirk’s proposal is therefore consistent with its longer-term strategy to realize full value from its core brands, particularly at a time when external financing conditions remain challenging and market volatility persists.
When Will THG Release Its Next Financial Update?
THG has confirmed that it will release its preliminary results for the fiscal year, along with its Q1 2025 trading update, on or around 30 April 2025. Given the company’s sharpened focus on profitability, growth, and deleveraging, investors and market watchers are anticipating detailed disclosures on revenue performance, operating margins, debt reduction milestones, and forward-looking commentary on segment-specific opportunities.
What Is the Latest Stock Performance and Sentiment Around THG PLC?
As of late April 2025, THG PLC’s stock performance reflects a phase of cautious stabilization following a volatile 2024. THG shares, listed on the London Stock Exchange under the ticker symbol THG.L, have traded in a wide range over the past twelve months, mirroring broader sectoral weakness across e-commerce and discretionary retail categories.
In the weeks leading up to the announcement rejecting Selkirk Capital Partners’ unsolicited offer, THG stock showed modest gains, supported by improving sentiment around its debt refinancing and streamlined post-Ingenuity demerger business model. However, overall market enthusiasm has remained subdued as investors await concrete evidence of profitability improvements and consistent free cash flow generation.
According to the latest trading data, THG’s share price is hovering around the £0.80–£0.85 range, compared to 52-week highs above £1.10 and lows near £0.55. This reflects a cautious, valuation-driven investor mindset that is not yet fully pricing in a rapid growth re-acceleration.
Buy/Sell/Hold Recommendation:
Current analyst consensus leans toward a Hold rating for THG PLC, reflecting a balance between improved financial fundamentals and persistent sector headwinds. While THG’s decisive rejection of Selkirk’s offer highlights management’s confidence, the market seeks further proof of sustained revenue growth, margin expansion, and cash generation before a widespread re-rating can occur. Near-term upside potential is considered moderate, contingent on THG’s forthcoming Q1 2025 financial update.
Institutional Flows and FII/DII Activity:
Institutional investor behavior shows cautious accumulation trends. Selective long-only funds have modestly increased their exposure to THG over the past quarter, focusing on the company’s strengthened balance sheet and reduced debt levels. However, there has not yet been broad-based aggressive buying.
Foreign Institutional Investors (FIIs) have largely maintained a neutral stance, while Domestic Institutional Investors (DIIs) in the United Kingdom have shown slightly stronger confidence, particularly pension funds and active managers seeking mid-cap growth exposure in undervalued sectors.
Overall Sentiment:
Post-announcement sentiment surrounding THG remains cautiously optimistic. The rejection of a seemingly opportunistic offer enhances management’s credibility but sustaining positive momentum will depend heavily on THG’s ability to demonstrate improved earnings quality, working capital management, and brand-led organic growth over the next two quarters.
Investors are advised to closely monitor the preliminary full-year results and Q1 2025 trading update due by 30 April 2025 for actionable insights into revenue momentum, operational leverage, and updated forward guidance.
Key Takeaways: THG’s Clear Focus on Independent Growth
THG’s firm rejection of Selkirk’s unsolicited Myprotein acquisition proposal reflects its confidence in its strategic plan and intrinsic brand value. The company’s enhanced financial position following the Ingenuity demerger and recent refinancing efforts has given it the leverage to dismiss offers that fail to meet its valuation and execution standards. With the Q1 2025 results pending, all eyes are now on how THG translates its strategic focus into tangible financial performance, especially in an increasingly competitive and health-conscious global marketplace.
As THG doubles down on organic growth initiatives, its decision to prioritize long-term shareholder value over short-term speculative gains could position it as a stronger and more resilient player in the evolving digital consumer landscape.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
